Thomas DiRaimondo's most recent trade in Janux Therapeutics Inc was a trade of 84,000 Stock option (right to buy) done . Disclosure was reported to the exchange on Jan. 2, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Janux Therapeutics Inc | Thomas DiRaimondo | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 84,000 | 84,000 | - | - | Stock option (right to buy) | |
Janux Therapeutics Inc | Thomas DiRaimondo | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 24,000 | 129,719 | - | 0 | Common Stock | |
Janux Therapeutics Inc | Thomas DiRaimondo | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 46.21 per share. | 27 Sep 2024 | 4,325 | 98,613 | - | 46.2 | 199,840 | Common Stock |
Janux Therapeutics Inc | Thomas DiRaimondo | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 47.23 per share. | 27 Sep 2024 | 675 | 97,938 | - | 47.2 | 31,877 | Common Stock |
Janux Therapeutics Inc | DiRaimondo Thomas | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 147,000 | 147,000 | - | - | Stock Option (right to buy) |